engleski

Serum platelet-activating factor acetyl-hydrolase activity in patients with angiographically established cerebrovascular stenosis

Oxidation of LDL cholesterol is considered to be one of the key stages in the early development of the atherosclerosis. The platelet-activating factor acetylhydrolase (PAF-AH) seems to have antiatherogenic role as it catabolises oxidized phospholipids on LDL. The aim of this study was to investigate the relation between serum PAF-AH activity in patients with cerebrovascular atherosclerotic changes of different degrees in accordance to the control no-stenosis group. The study comprised 32 patients mean age of 67 years (range 49-80 years) with different degrees of stenosis, established angiographically. The control no-stenosis group consisted of 35 apparently healthy individuals mean age of 55 years (range 44-76 years), with normal cerebral arteries on ultrasound examination. PAF-AH activity was measured with the new automated spectrophotometric assay (AZWELL Auto PAF-AH, Osaka, Japan) on an Olympus AU-600 automatic analyzer (Olympus Mishima Co., Ltd. Shizuoka, Japan). Serum PAF-AH activities did not differ significantly between patient's group with stenosis and the control no-stenosis group (median values 351 U/L versus 380 U/L, >0, 05). Serum PAF-AH activity correlated in control group and the group of patients with total cholesterol (r=0.57 and r=0.56, p<0.05, respectively)and LDL cholesterol (r=0.64 and r=0.48, p<0.05, respectively). The obtained results suggest that serum PAF-AH activity is not associated with cerebrovascular stenosis of different degrees.

biochemical risk factors of atherosclerosis; total homocysteine; total antioxidative status; high-sensitivity C-reactive protein; cerebrovascular stenosis; angiography

nije evidentirano